Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

YieldMax NVDA Option Income Strategy ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

YieldMax NVDA Option Income Strategy ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $13.03, while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

NVDYRXRX
Sector
Income / Options OverlayHealth
52-Week High
$17.96$6.79
52-Week Low
$11.58$2.84
Market Cap
$1.81B
Enterprise Value
$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax NVDA Option Income Strategy ETF

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.

Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax NVDA Option Income Strategy ETF

NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

Read more on NVDY

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX